Broad therapeutic benefits in patients with probable vascular dementia or Alzheimer's disease with cerebrovascular disease treated with galantamine

Annals of the New York Academy of Sciences

Volumn 977, Issue , 2002, Pages 487-492

  Lilienfeld, S ^a   Kurz, A ^b  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Alzheimer's disease (AD); Cerebrovascular disease (CVD); Galantamine; Vascular dementia (VaD)

Indexed keywords

CHOLINESTERASE INHIBITOR; GALANTAMINE; MEMANTINE; PLACEBO; PROPENTOFYLLINE;

ALZHEIMER DISEASE; ATHEROSCLEROSIS; CEREBROVASCULAR DISEASE; CHOLINESTERASE INHIBITION; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DOUBLE BLIND PROCEDURE; GASTROINTESTINAL DISEASE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MIXED DEPRESSION AND DEMENTIA; MULTICENTER STUDY; MULTIINFARCT DEMENTIA; NEUROPATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 0036449655     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2002.tb04855.x     Document Type: Conference Paper

References (20)

1. Rockwood, K. et al. 2000. Prevalence and outcomes of vascular cognitive impairment. Neurology 54: 447-451.
2. Evans, D.A. et al. 1989. Prevalence of Alzheimer's disease in a community population of older persons: Higher than previously reported. JAMA 262: 2551-2556.
3. Kalaria, R.N. & C. Ballard. 1999. Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis. Assoc. Disord. 13(suppl. 3): S115-S123.
4. Erkinjuntti, T. 2001. Clinical deficits of Alzheimer's disease with cerebrovascular disease and probable VaD. Int. J. Clin. Pract. Suppl., pp. 14-23.
5. Groves, W.C. et al. 2000. Vascular dementia and Alzheimer's disease: Is there a difference? A comparison of symptoms by disease duration. J. Neuropsychiatry Clin. Neurosci. 12: 305-315.
6. Erkinjuntti, T. 2001. Cerebrovascular dementia: Pathophysiology, diagnosis, and treatment. CNS Drugs, pp. 35-48.
7. Rother, M. et al. 1998. Propentofylline in the treatment of Alzheimer's disease and vascular dementia: A review of phase III trials. Dement. Geriatr. Cogn. Disord. 9(suppl. 1): 36-43.
8. Mielke, R. et al. 1998. Propentofylline in the treatment of vascular dementia and Alzheimer-type dementia: Overview of phase I and phase II clinical trials. Alzheimer Dis. Assoc. Disord. 12(suppl. 2): S29-S35.
9. Geerts, H. & C. Grantham. 2001. Should We be Studying Cholinergic Drugs for the Treatment of Vascular Dementia? Submitted.
10. Maelicke, A. 2001. The pharmacological rationale for treating vascular dementia with galantamine (Reminyl). Int. J. Clin. Pract. Suppl., pp. 24-28.
11. Tariot, P. 2001. Current status and new developments with galantamine in the treatment of Alzheimer's disease. Exp. Opin. Pharmacother. 2(12): 2027-2049.
12. Raskind, M.A. & P. Kershaw. 2002. The cognitive benefits of galantamine are sustained for at least 36 months: Results of a long-term extension trial in Alzheimer's disease. Presentation at the 2002 American Association for Geriatric Psychiatry 15th Annual Meeting (23-27 February 2002), Orlando.
13. Samochocki, M., E.X. Albuquerque et al. 2000. Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR. Acta Neurol. Scand. Suppl. 176: 68-73.
14. Maelicke, A. et al. 2001. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. Biol. Psychiatry 49: 279-288.
15. Erkinjuntti, T. et al. 2002. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: A randomized trial. Lancet 359(9314): 1283-1290.
16. Bullock, R. & S. Lilienfeld. 2001. Poster presented at the XVIIth World Congress of Neurology (17-22 June 2001), London.
17. McKhann, G. et al. 1984. Clinical diagnosis of Alzheimer's disease. Neurology 34: 939-944.
18. Gold, G. et al. 1997. Sensitivity and specificity of newly proposed clinical criteria for possible vascular dementia. Neurology 49: 690-694.
19. Kittner, B. 1999. Clinical trials of propentofylline in vascular dementia: European/Canadian Propentofylline Study Group. Alzheimer Dis. Assoc. Disord. 13(suppl. 3): S166-S171.
20. Wilcock, G. et al. 2000. Neuro-radiological findings and the magnitude of cognitive benefit by memantine treatment: A subgroup analysis of two placebo-controlled clinical trials in vascular dementia. Eur. Neuropsychopharmacol. 10(suppl. 3): S360.